Repertoire Immune Medicines Collaborates with Genentech to Develop T cell-Targeted Therapies for an Autoimmune Disease
Shots:
- Repertoire & Genentech have entered into a collaboration & license agreement to identify & develop novel T cell-targeted therapies for an autoimmune disease, leveraging Repertoire’s DECODE platform
- As per the deal, Genentech will handle preclinical & clinical development along with global marketing in exchange for $35M upfront & ~$730M in development, regulatory & commercial milestones as well as tiered royalties while Repertoire will lead target discovery activities
- DECODE platform uniquely maps the entire immune synapse in pts, providing a comprehensive & in-depth understanding of the interactions between T cell receptors & their corresponding antigenic epitopes
Ref: Prnewswire | Image: Repertoire & Genentech
Related News:- Genentech Reports the FDA's sBLA Acceptance for Gazyva to Treat Lupus Nephritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
